Clinical factors and association with CR at 12 months
| Risk factor . | Events/patients, n (%) . | OR (95% CI) . |
|---|---|---|
| Age (continuous) | — | 1.02 (0.99-1.05) |
| Disease type | ||
| PV | 11/50 (22) | 2.68 (1.17-6.15) |
| ET | 28/65 (43) | — |
| Gender | ||
| Male | 20/57 (35) | 0.90 (0.42-1.95) |
| Female | 19/58 (33) | — |
| HU group | ||
| Resistant | 10/37 (27) | 1.54 (0.65-3.65) |
| Intolerable | 28/77 (36) | — |
| Prior thrombosis (disease-related) | ||
| Yes | 10/32 (31) | 1.18 (0.49-2.83) |
| No | 29/83 (35) | — |
| Disease duration (continuous) | — | 0.99 (0.98-1.00) |
| Maximum dose PEG received, µg/wk | ||
| 45 | 8/26 (31) | 1.39 (0.47-4.11) |
| 90 | 13/34 (38) | 1.39 (0.41-4.65) |
| 135 | 8/21 (38) | 0.98 (0.32-2.99) |
| 180 | 10/33 (30) | — |
| ECOG performance status, grade | ||
| 0 | 26/77 (34) | 1.02 (0.45-2.32) |
| 1/2 | 13/38 (34) | — |
| CALR mutation | ||
| No | 23/82 (28) | 3.34 (1.28-8.67) |
| Yes | 13/23 (56) | — |
| JAK2 mutation | ||
| No | 14/26 (54) | 0.33 (0.13-0.83) |
| Yes | 22/79 (28) | — |
| Risk factor . | Events/patients, n (%) . | OR (95% CI) . |
|---|---|---|
| Age (continuous) | — | 1.02 (0.99-1.05) |
| Disease type | ||
| PV | 11/50 (22) | 2.68 (1.17-6.15) |
| ET | 28/65 (43) | — |
| Gender | ||
| Male | 20/57 (35) | 0.90 (0.42-1.95) |
| Female | 19/58 (33) | — |
| HU group | ||
| Resistant | 10/37 (27) | 1.54 (0.65-3.65) |
| Intolerable | 28/77 (36) | — |
| Prior thrombosis (disease-related) | ||
| Yes | 10/32 (31) | 1.18 (0.49-2.83) |
| No | 29/83 (35) | — |
| Disease duration (continuous) | — | 0.99 (0.98-1.00) |
| Maximum dose PEG received, µg/wk | ||
| 45 | 8/26 (31) | 1.39 (0.47-4.11) |
| 90 | 13/34 (38) | 1.39 (0.41-4.65) |
| 135 | 8/21 (38) | 0.98 (0.32-2.99) |
| 180 | 10/33 (30) | — |
| ECOG performance status, grade | ||
| 0 | 26/77 (34) | 1.02 (0.45-2.32) |
| 1/2 | 13/38 (34) | — |
| CALR mutation | ||
| No | 23/82 (28) | 3.34 (1.28-8.67) |
| Yes | 13/23 (56) | — |
| JAK2 mutation | ||
| No | 14/26 (54) | 0.33 (0.13-0.83) |
| Yes | 22/79 (28) | — |